Chugai sold Roche half of itself in 2002, kept its independence, and became No.1

By the early 2000s Chugai Pharmaceutical was Japan's 10th-largest drugmaker, too small to fund global R&D or build overseas sales as the industry consolidated into giants. President Osamu Nagayama wanted Chugai to become Japan's number one pharmaceutical company — without disappearing into a foreign acquirer.

In October 2002 Chugai struck an unusual alliance: Roche took a 50.1% equity stake, making Chugai a member of the Roche Group, yet Chugai retained its own management, its Tokyo listing and its corporate identity. Chugai received exclusive rights to develop and market Roche's innovative products in Japan, while Roche gained Chugai's R&D pipeline for its global distribution network.

The structure held. Two decades on, Roche still owns about 59.9% and has repeatedly declined to take full control, saying the arrangement works — unlike its $47 billion full buyout of Genentech. By 2024 the alliance had transformed Chugai from Japan's 10th-largest pharma into its market leader in oncology and by market capitalization.

Japan's 10th-largest drugmaker became its leader in oncology and market value by 2024, with exclusive Japanese rights to Roche's portfolio.

Chugai's constraint was reach, not science — the alliance bought global distribution without a loss of autonomy.

Keeping the listing and management let Chugai preserve its identity and talent, avoiding the post-merger exodus that kills acquirees.

Exclusive Japanese rights to Roche's portfolio gave Chugai a revenue engine it could never have built alone.

Roche benefited enough from the light-touch structure that it chose not to consolidate, keeping the incentives aligned for over 20 years.

A majority stake is not a takeover if you negotiate the opposite: trade equity for reach while contractually protecting management, listing and identity, and both sides compound.

The alliance endures: Roche held 59.9% and publicly ruled out changes even as the yen weakened and analysts speculated about a full buyout. Chugai remains listed in Tokyo and operates as Roche's arm in Japan while exporting its own discoveries — among them the antibody Actemra — through Roche's global network.